INVOKAMET Drug Patent Profile

Which patents cover Invokamet, and when can generic versions of Invokamet launch?

Invokamet is a drug marketed by Janssen Pharms and is included in two NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and seventy-one patent family members in forty-eight countries.

The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Invokamet

Invokamet was eligible for patent challenges on March 29, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 6, 2030. This may change due to patent challenges or generic licensing.

There have been twenty-six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for INVOKAMET

International Patents:	271
US Patents:	4
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Drug Prices:	Drug price information for INVOKAMET
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for INVOKAMET
What excipients (inactive ingredients) are in INVOKAMET?	INVOKAMET excipients list
DailyMed Link:	INVOKAMET at DailyMed

See drug prices for INVOKAMET

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for INVOKAMET

NDA:

204353

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for INVOKAMET

Drug Class	Biguanide Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	P-Glycoprotein Inhibitors Sodium-Glucose Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for INVOKAMET

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
INVOKAMET	Tablets	canagliflozin; metformin hydrochloride	50 mg/500 mg 50 mg/1000 mg 150 mg/500 mg 150 mg/1000 mg	204353	6	2017-03-29

US Patents and Regulatory Information for INVOKAMET

INVOKAMET is protected by four US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-003	Sep 20, 2016		RX	Yes	No					Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-001	Sep 20, 2016		RX	Yes	No					Y
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016		RX	Yes	No
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-001	Sep 20, 2016		RX	Yes	No
Janssen Pharms	INVOKAMET XR	canagliflozin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	205879-002	Sep 20, 2016		RX	Yes	No
Janssen Pharms	INVOKAMET	canagliflozin; metformin hydrochloride	TABLET;ORAL	204353-001	Aug 8, 2014		RX	Yes	No			Y

Expired US Patents for INVOKAMET

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Pharms	INVOKAMET	canagliflozin; metformin hydrochloride	TABLET;ORAL	204353-004	Aug 8, 2014
Janssen Pharms	INVOKAMET	canagliflozin; metformin hydrochloride	TABLET;ORAL	204353-001	Aug 8, 2014
Janssen Pharms	INVOKAMET	canagliflozin; metformin hydrochloride	TABLET;ORAL	204353-002	Aug 8, 2014
Janssen Pharms	INVOKAMET	canagliflozin; metformin hydrochloride	TABLET;ORAL	204353-003	Aug 8, 2014

International Patents for INVOKAMET

When does loss-of-exclusivity occur for INVOKAMET?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Honduras

Hungary

India

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

New Zealand

Nicaragua

Peru

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering INVOKAMET around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	077464
Argentina	118805
Australia	2010270669
Australia	2015203067
Australia	2017200445
Brazil	112012000502

Supplementary Protection Certificates for INVOKAMET

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1651658	2014/029	Ireland		PRODUCT NAME: CANAGLIFLOZIN; REGISTRATION NO/DATE: EU/1/13/884/001-004 20131119
1651658	PA2014008	Lithuania		PRODUCT NAME: CANAGLIFOZINUM; REGISTRATION NO/DATE: EU/1/13/884/001 - EU/1/13/884/004, 2013 11 15 EU/1/13/884/005 - EU/1/13/884/008 20131115
1651658	CA 2014 00024	Denmark		PRODUCT NAME: CANAGLIFLOZIN, HERUNDER CANAGLIFLOZINHEMIHYDRAT; REG. NO/DATE: EU/1/13/884/001-008 20131115
1651658	C300670	Netherlands		PRODUCT NAME: CANAGLIFLOZINE; REGISTRATION NO/DATE: EU/1/13/884/001-008 20131118
1651658	92426	Luxembourg		PRODUCT NAME: CANAGLIFLOZINE
1651658	C20140011 00102	Estonia		PRODUCT NAME: KANAGLIFLOSIIN;REG NO/DATE: K(2013)8171 (LOPLIK) 15.11.2013

INVOKAMET (canagliflozin + metformin) market dynamics and financial trajectory: exclusivity, competition, pricing, and revenue exposure

Last updated: July 21, 2026

Executive summary: INVOKAMET (canagliflozin/metformin; Janssen) has faced sustained competitive pressure from GLP-1 and other SGLT2 inhibitor classes, plus tightening payer coverage for older branded diabetes combinations. Financial trajectory is characterized by (1) slower-than-peak brand growth after initial SGLT2 momentum, (2) accelerated erosion as lower-cost generics of metformin and class rivals gained formulary share, and (3) continuing shifts in portfolio allocation toward broader SGLT2 and cardiovascular outcome franchises and toward incretin-based therapies. Key value is concentrated in U.S. brand access and persistent SGLT2 demand where INVOKAMET is preferred over single-agent or alternative combination products.

What is INVOKAMET and how does it fit into the diabetes and SGLT2 market?

Short answer: INVOKAMET is an oral fixed-dose combination of canagliflozin (an SGLT2 inhibitor) and metformin used in type 2 diabetes, leveraging SGLT2 glycemic control with metformin’s foundational role.

Mechanism and payer-friendly positioning

• Canagliflozin (SGLT2 inhibitor): reduces blood glucose by increasing urinary glucose excretion; also links to cardiorenal benefits that supported payer adoption of the SGLT2 class.
• Metformin: establishes a low-cost baseline in standard of care and supports “add-on” logic to intensify therapy.

Market dynamic: Combination products are typically adopted when payers and prescribers prefer reducing pill burden versus using separate generics. That balance weakens over time as generics, biosimilar-like substitution dynamics, and class-wide competitive access intensify.

Product breadth and segment exposure

• INVOKAMET sits within the wider SGLT2 competitive set: empagliflozin and dapagliflozin combination offerings and their fixed-dose metformin combinations.
• It competes with:
  • Separate generic metformin + brand SGLT2 strategies.
  • Other branded diabetes combinations (including DPP-4 and fixed-dose incretin combinations, where payer preference shifts toward GLP-1).

How fast did INVOKAMET revenue grow, and what has driven its financial trajectory since launch?

Short answer: INVOKAMET’s financial trajectory has reflected SGLT2’s early uptake cycle, followed by market maturation and substitution pressure from other SGLT2 brands and incretin-led formularies.

Revenue drivers

1. SGLT2 adoption curve: Early SGLT2 category growth supported brand uptake, especially after cardiovascular outcomes evidence increased clinical confidence and payer justification.
2. Combination uptake: Fixed-dose combinations typically gain share when they simplify titration and adherence, and when payer formularies encourage combination use rather than two-drug regimens.
3. Therapeutic intensity and comorbidity: SGLT2 positioning for cardiorenal populations expanded demand beyond pure glycemic control, supporting longer persistence than many older diabetes agents.

Revenue headwinds

1. Class competition: Multiple SGLT2 inhibitors are available with similar clinical positioning, producing price and access pressure.
2. GLP-1 displacement: GLP-1 receptor agonists and dual incretin therapies increasingly moved into earlier lines, squeezing SGLT2-only or combination share growth even where SGLT2 remained important for comorbidity.
3. Metformin generic baseline: Since metformin is generic, separate prescribing becomes a lower-cost path for payers, especially once combination product rebates weaken relative to alternatives.

What “financial trajectory” looks like in practice

• Early-cycle sales are often driven by:
  • formulary adoption,
  • initiation volume,
  • prescriber sampling and early switching.
• Later-cycle sales stabilize or decline when:
  • insurers steer to preferred brands within the SGLT2 set,
  • generic metformin + preferred SGLT2 becomes the lowest net-cost regimen,
  • patient churn to GLP-1 accelerates.

What market forces are shaping INVOKAMET sales: payer coverage, price compression, and channel strategy?

Short answer: Payer coverage and net price dynamics are the core determinants of INVOKAMET’s commercial trajectory, alongside therapeutic switching toward incretins.

Formulary and rebate mechanics

• SGLT2 inhibitors are heavily managed through:
  • tier placement,
  • prior authorization for certain patient profiles,
  • step therapy across agents and combinations,
  • rebate competition among brand products.
• As more biosimilar-style substitution does not apply here, the equivalent “substitution mechanism” is net-cost minimization among brand SGLT2 options and generic metformin pairings.

Price compression pattern

• When multiple SGLT2 products compete, gross-to-net discounting expands.
• Fixed-dose combinations can face disproportionate pressure because payers can often match clinical outcomes using generic metformin plus the preferred SGLT2 monotherapy.

Channel mix

• High-volume buyers in diabetes include:
  • large PBMs,
  • Medicare Part D,
  • commercial plans with disease management programs.
• These buyers drive:
  • utilization management,
  • formulary steering,
  • contract renewal cycles that can shift share quickly between preferred SGLT2 brands.

Which competitors most directly challenge INVOKAMET in fixed-dose diabetes combination use?

Short answer: The most direct threats are other SGLT2 + metformin fixed-dose combinations and payer-favored strategies using generic metformin plus another preferred SGLT2.

Peer fixed-dose competition

• Empagliflozin/metformin fixed-dose options (e.g., brand combinations in market).
• Dapagliflozin/metformin fixed-dose options (where applicable).
• Separate metformin + preferred SGLT2 prescribing, which is frequently the lowest net-cost route.

Cross-class competition

• GLP-1 and dual incretin therapies increasingly capture initiation share in earlier treatment stages.
• As GLP-1 adoption rises, incremental share gains for SGLT2 combinations slow even if SGLT2 remains clinically valuable for cardiorenal risk.

Clinical switching

• Switching is driven by:
  • formulary access,
  • side-effect profiles and tolerance,
  • adherence and pill burden,
  • insurer preferences aligned with outcomes evidence and cost.

What is the Orange Book status of INVOKAMET, and when do generic risks emerge?

Short answer: Generic entry risk timing depends on the patent estate for the specific INVOKAMET strengths and dosage forms, and on any listed formulation, method-of-use, and combination composition patents in the Orange Book.

How to assess generic risk for combination products

• Orange Book typically includes patents across:
  • active ingredient and composition of matter (canagliflozin and combination claims),
  • formulation (pill matrix, film coating, stability, dissolution profile),
  • method-of-use (indications and dosing regimens),
  • manufacturing.
• For fixed-dose combinations, challengers can target:
  • a listed method-of-use patent,
  • a formulation patent,
  • or a combination-specific composition patent.

Commercial impact: Even when generic metformin exists, a fully generic INVOKAMET equivalent must satisfy combination and brand-protecting patents. In practice, the threat is either:

• Paragraph IV challenges on listed patents leading to generic launches, or
• “authorized” or lower-cost branded alternatives via negotiated settlements.

What patents protect INVOKAMET, and how strong is the patent estate versus generic launch scenarios?

Short answer: INVOKAMET’s protection is based on a layered strategy: active ingredient claims for canagliflozin, combination/formulation patents covering fixed-dose delivery, and potentially method-of-use claims tied to diabetes management.

Key estate components to evaluate

• Composition/formulation patents for fixed-dose stability and release characteristics.
• Method-of-use patents aligned to label indications and dosing strategies.
• Late-expiring continuation filings that can delay generic “at-risk” launch.

How to interpret strength for business planning

• A “strong” estate usually has:
  • multiple listed patents with staggered expirations,
  • claims that are not easily designed around,
  • a history of enforcement or litigation settlements in the class.

Business implication: Even when one patent expires, remaining listed patents can sustain brand position through delayed generic entry for combination dosage forms.

What Paragraph IV challenges and patent litigation affect INVOKAMET and its generic entry risk?

Short answer: INVOKAMET’s generic risk profile is tied to whether ANDA filers have pursued Paragraph IV certifications against the Orange Book-listed patents for its strengths.

Why litigation matters commercially

• Litigation affects:
  • launch timing (automatic stays),
  • negotiated settlements that may introduce “delayed entry” agreements,
  • the availability of authorized generics and “launch at risk” timelines.

How does FDA regulatory status shape INVOKAMET’s competitive landscape?

Short answer: INVOKAMET is an FDA-approved fixed-dose combination under the standard NDA pathway, and competitor entry is governed by ANDA pathways for generics or NDA/BLA for other brand combinations.

What matters for competitive timing

• Generic pathway: ANDA approval for therapeutically equivalent fixed-dose combinations depends on patent resolution or expiration.
• Label stability: If INVOKAMET’s label changes via new safety communications or dosing updates, this can affect the usability of generics for the same patient segments.

How does INVOKAMET compare with other diabetes brands on market access and utilization?

Short answer: INVOKAMET competes more on formulary positioning within the SGLT2+metformin combination category than on clinical differentiation, since multiple class rivals offer comparable glycemic mechanisms and cardiorenal benefits.

Competitive differentiation channels

• Access: Preferred tier placement and PA criteria.
• Net price: Contracting position with PBMs and payers.
• Switching inertia: Chronic patients using stable regimens often resist changes unless coverage forces switching.
• Adherence: Fixed-dose combination reduces pill burden versus two-agent regimens, supporting persistence where payers prefer it.

Regional and payer-specific dynamics: where is INVOKAMET likely to hold share longer?

Short answer: Share durability typically tracks payer contract structure and Medicare/Commercial tiering that locks patients into stable SGLT2 regimens.

U.S. commercial vs Medicare

• Commercial: more sensitive to managed care contracts and PBM steering.
• Medicare Part D: driven by formularies and plan design; once a plan restricts access, patients may switch at renewal or during PA failures.

What does INVOKAMET’s financial exposure imply for Janssen’s broader diabetes and cardiorenal franchise?

Short answer: INVOKAMET’s role is primarily to monetize canagliflozin within the fixed-dose diabetes segment, but overall portfolio growth depends more on the broad SGLT2 brand and its cardiorenal use than on combination-only momentum.

Strategic portfolio interpretation

• As GLP-1 adoption grows, SGLT2 portfolios tend to emphasize:
  • persistence in cardiorenal populations,
  • differentiated outcomes narratives,
  • expanded patient subgroups where SGLT2 benefits remain distinct.
• Fixed-dose combinations support adherence but are vulnerable to payer cost minimization through separate generic metformin.

Key timelines to monitor for revenue inflection

Short answer: Monitor patent expiration and litigation outcomes for each INVOKAMET strength, plus contract renewal cycles that influence preferred SGLT2 selection.

Timeline framework (business use)

• Patent expiration windows: by strength and dosage form, based on Orange Book listed dates.
• Litigation and settlement outcomes: determines whether generic launches occur at the earliest legally possible date or later.
• Formulary contract renewals: can shift preferred SGLT2 brand share within a few quarters even before patent expiry.

Key Takeaways

• INVOKAMET’s market dynamics are dominated by payer formulary management and net price competition within the SGLT2 class, amplified by the persistent generic baseline of metformin.
• Financial trajectory tracks the SGLT2 adoption cycle early, then stabilizes under class competition and incremental pressure from GLP-1-based prescribing shifts.
• Generic entry risk is a function of Orange Book-listed patents specific to canagliflozin/metformin fixed-dose formulations, plus Paragraph IV litigation outcomes that determine launch timing.
• The commercial durability of INVOKAMET depends less on clinical uniqueness and more on continued preferred access versus lower net-cost alternatives using separate generic metformin plus payer-favored SGLT2 brands.

FAQs

1. Which payers are most likely to steer INVOKAMET patients to separate generic metformin plus an alternate SGLT2?
2. How do PA and step-therapy policies affect INVOKAMET persistence in Medicare Part D versus commercial plans?
3. What Orange Book patent types most often delay generic fixed-dose SGLT2/metformin combinations?
4. How does incretin therapy adoption change long-term utilization of SGLT2/metformin combinations?
5. What litigation outcomes typically shift market share for branded diabetes combinations ahead of patent expiry?

References

1. Bloomberg Law. Orange Book and patent litigation database (accessed via relevant Orange Book and FDA regulatory sources).
2. FDA Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations (accessed via product-specific listings for INVOKAMET).
3. FDA Drug Labels (INVOCANMET/canagliflozin and metformin product labeling for approved indications and dosing).

DrugChatter Q&A for INVOKAMET

Invokamet extended release patent?
Invokamet formulation composition patent?
Invokamet xr side effects?
Invokamet prescription assistance program?